Examples of using Cuscc in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Monitoring for skin lesions should occur as described for cuSCC.
Cases of cuSCC can be managed with excision
It has not been determined whether cuSCC is related to Erivedge treatment.
Cases of cuSCC have been reported in patients treated with vemurafenib.
Patients with advanced BCC have an increased risk of developing cuSCC.
CuSCC was very commonly reported and was most commonly treated by local excision.
Taking the combination of Mekinist and dabrafenib may cause a different type of skin cancer called cutaneous squamous cell carcinoma cuSCC.
Cases of cuSCC have been reported in advanced BCC patients treated with Erivedge.
including cuSCC, decreased appetite, and cardiac disorders.
In patients who develop cuSCC, it is recommended to continue the treatment without dose adjustment.
Therefore, all patients should be monitored routinely while taking Erivedge, and cuSCC should be treated according to the standard of care.
The incidence of cuSCC in vemurafenib-treated patients across studies was approximately 20.
Up to 3 in 100 people taking Mekinist in combination with dabrafenib may develop a different type of skin cancer called cutaneous squamous cell carcinoma cuSCC.
CuSCC usually occurred early in the course of treatment with a median time to the first appearance of 7 to 8 weeks.
Dose modifications or interruptions are not recommended for adverse reactions of cutaneous squamous cell carcinoma(cuSCC) or new primary melanoma see section 4.4.
Cases of cuSCC(including keratoacanthoma) have been reported in patients treated with trametinib in combination with dabrafenib.
Dose modifications are not recommended for adverse reactions of cutaneous squamous cell carcinoma(cuSCC) or new primary melanoma see dabrafenib SmPC for further details.
Cases of cuSCC were typically managed with simple excision,
In the Phase III study MEK115306, cuSCC occurred in 3%(6/209) of patients receiving trametinib
Cases of cuSCC(including keratoacanthoma) have been reported in patients
In the Phase III study MEK116513, cuSCC occurred in 1%(5/350) of patients receiving trametinib
Cases of cuSCC(which include those classified as keratoacanthoma
Cases of cuSCC should be managed by dermatological excision